✦ LIBER ✦

N-0923, A novel soluble dopamine D2 agonist in the treatment of parkinsonism

✍ Scribed by Vincent P. Calabrese; K. Alvin Lloyd; Pasquale Brancazio; Eugene Cefali; Pauline Martin; James Wall Jr.; Dominic Sica

Publisher: John Wiley and Sons
Year: 1998
Tongue: English
Weight: 614 KB
Volume: 13
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.870130503

No coin nor oath required. For personal study only.

✦ Synopsis

N-0923, a novel aminotetralin dopamine D2 agonist, was shown to effectively reverse parkinsonian symptoms in nine dopa/agonist-responsive Parkinson's disease patients. The drug was given up to 4.5 hours by continuous intravenous (i.v.) infusion using an i.v. pump. The onset of anti-parkinsonian effect was seen within minutes of the initiation of the infusion and was absent within 90 minutes of cessation of the infusion. The short elimination half-life of N-0923 (90 min) would allow for the rapid initiation of drug effect when necessary and at the same time permit the effect to be terminated quickly if necessary. The drug would be useful in situations where oral medication is not feasible or is associated with erratic absorption. The patients tolerated the drug well. Dose escalation load was limited by nausea and vomiting. It should be noted that the doses were increased until these symptoms occurred, but therapeutic effects were noted well before the side effects occurred. Using a modified Columbia scale, maximum improvement consisted of a 27-95% drop in score. Maximum response was obtained at infusion rates varying from 2-16 microg/kg per hour and at blood levels of 0.11-1.49 microg/mL.

📜 SIMILAR VOLUMES

N-0923, a selective dopamine D2 receptor

N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease

✍ Dr. J. D. Belluzzi; E. F. Domino; J. M. May; K. S. Bankiewicz; D. A. McAfee 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 800 KB

## Abstract Certain aminotetralins are known to be potent dopamine D~2~ receptor agonists. N‐0923, [‐]2‐(N‐propyl‐N‐2‐thienylethylamino)‐5‐hydroxytetralin HCl, recognizes the high and low affinity states of the D~2~ receptor in membranes from bovine caudate with a K~low~ of 79 nM. The selectivity r

PHNO, a novel dopamine agonist, in anima

PHNO, a novel dopamine agonist, in animal models of parkinsonism

✍ Dr. William Koller; Gregory Herbster; John Gordon 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB

PHNO, a naphthoxazine compound, was investigated in animal models of central dopaminergic activity. The drug in doses of 5-300 micrograms/kg when administered subcutaneously, or transdermally, induced stereotypic behavior in rats which was blocked by haloperidol but not by reserpine pretreatment. In

Transdermal dopaminergic D2 receptor ago

Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study

✍ J. Thomas Hutton; Leo Verhagen Metman; Thomas N. Chase; Jorge L. Juncos; William 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 35 KB 👁 1 views

## Abstract N‐0923 is a non‐ergot, dopaminergic D~2~ agonist designed to be transdermally available. It has anti‐parkinsonian effects when infused intravenously. An adhesive matrix patch was developed to deliver N‐0923 transdermally (N‐0923 TDS). In this phase II trial, we evaluated the effectiven

Antiparkinsonian effects of the novel D3

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors

✍ Michael P. Hill; Paula Ravenscroft; Steven G. McGuire; Jonathan M. Brotchie; Ala 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

L-dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor agonists such as the novel agent S32504, since they exert antiparkinsonian properties in the absence of dyskinesia. An important question concerns the roles of D2 vs. D3 recept

Pharmacokinetics of the dopamine D2 agon

Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats

✍ P. J. Swart; R. A. de Zeeuw 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 503 KB

The pharmacokinetics of the dopamine D2 agonist S( -)-2-(N-propyl-N2-thienylethylamino)-5-hydroxytetralin (1, N-0923) after intravenous, intraperitoneal, and oral administration was studied in freely moving male and female albino Wistar rats. In all cases, the dose was

Repeated treatment with the selective ka

Repeated treatment with the selective kappa opioid agonist U-69593 produces a marked depletion of dopamine D2 receptors

✍ Sari Izenwasser; Jane B. Acri; Paul M. Kunko; Toni Shippenberg 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

U-69593, the selective -opioid agonist, was repeatedly administered in single daily injections (0.32 mg/kg) to male, Sprague-Dawley rats. Two or ten days later, the rats were euthanized and dopamine D 1 and D 2 receptors were measured using ( 3 H]SCH 23390 or [ 3 H]sulpiride, respectively, in caudat